Form 4: Vir Biotechnology CAO Executes Stock Sale

Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, sold 379 shares of common stock on June 1, 2026.

Summary

• Brent Sabatini, SVP and Chief Accounting Officer, sold 379 shares of Vir Biotechnology common stock.
• The transaction occurred on June 1, 2026, at a price of $9.45 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2025.
• Following the transaction, the reporting person retains 61,902 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-established 10b5-1 plan, which is a routine administrative action.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.

Negatives

• Insider selling activity can sometimes be perceived negatively by market participants as a signal of management sentiment.

Risks

• Market volatility affecting the share price of Vir Biotechnology.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate practice for liquidity and diversification, and typically does not reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to manage equity holdings while maintaining compliance with insider trading regulations.

Stakeholder Impact

• Minimal impact expected on shareholders as the transaction size is small relative to total outstanding shares.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Vir Biotechnology, VIR, Insider Trading, Form 4, Brent Sabatini, Biotech